Ginkgo Bioworks Net Worth
Ginkgo Bioworks Net Worth Breakdown | DNA |
Ginkgo Bioworks Net Worth Analysis
Ginkgo Bioworks' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Ginkgo Bioworks' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Ginkgo Bioworks' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Ginkgo Bioworks' net worth analysis. One common approach is to calculate Ginkgo Bioworks' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Ginkgo Bioworks' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Ginkgo Bioworks' net worth. This approach calculates the present value of Ginkgo Bioworks' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Ginkgo Bioworks' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Ginkgo Bioworks' net worth. This involves comparing Ginkgo Bioworks' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Ginkgo Bioworks' net worth relative to its peers.
Enterprise Value |
|
To determine if Ginkgo Bioworks is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Ginkgo Bioworks' net worth research are outlined below:
| Ginkgo Bioworks generated a negative expected return over the last 90 days | |
| Ginkgo Bioworks has high historical volatility and very poor performance | |
| Ginkgo Bioworks has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 227.04 M. Reported Net Loss for the year was (547.03 M) with profit before taxes, overhead, and interest of 182.5 M. | |
| Ginkgo Bioworks Holdings has about 1.32 B in cash with (319.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.84. | |
| Over 81.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from nypost.com: Biohackers and stars like Hailey Bieber are obsessed with this longevity molecule but is it the holy grail of supplements |
Ginkgo Bioworks uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Ginkgo Bioworks Holdings. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ginkgo Bioworks' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Ginkgo Bioworks Target Price Consensus
Ginkgo target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Ginkgo Bioworks' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 6 | Hold |
Most Ginkgo analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Ginkgo stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Ginkgo Bioworks Holdings, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationGinkgo Bioworks Target Price Projection
Ginkgo Bioworks' current and average target prices are 6.92 and 8.30, respectively. The current price of Ginkgo Bioworks is the price at which Ginkgo Bioworks Holdings is currently trading. On the other hand, Ginkgo Bioworks' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Ginkgo Bioworks Target Price
Know Ginkgo Bioworks' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ginkgo Bioworks is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ginkgo Bioworks Holdings backward and forwards among themselves. Ginkgo Bioworks' institutional investor refers to the entity that pools money to purchase Ginkgo Bioworks' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Forbes J M & Co | 2024-12-31 | 701.7 K | Millennium Management Llc | 2024-12-31 | 670.1 K | Two Sigma Investments Llc | 2024-12-31 | 645.4 K | Sb Investment Advisers (uk) Ltd | 2024-12-31 | 610.7 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 565.3 K | Goldman Sachs Group Inc | 2024-12-31 | 547.6 K | D. E. Shaw & Co Lp | 2024-12-31 | 546.4 K | Geode Capital Management, Llc | 2024-12-31 | 437 K | Ubs Group Ag | 2024-12-31 | 386.3 K | Bank Of America Corp | 2024-12-31 | 3.8 M | Viking Global Investors Lp | 2024-12-31 | 3.6 M |
Follow Ginkgo Bioworks' market capitalization trends
The company currently falls under 'Small-Cap' category with a total capitalization of 409.37 M.Market Cap |
|
Project Ginkgo Bioworks' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | (0.44) | (0.46) | |
| Return On Assets | (0.40) | (0.42) | |
| Return On Equity | (0.76) | (0.80) |
When accessing Ginkgo Bioworks' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Ginkgo Bioworks' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Ginkgo Bioworks' profitability and make more informed investment decisions.
Please note, the presentation of Ginkgo Bioworks' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ginkgo Bioworks' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ginkgo Bioworks' management manipulating its earnings.
Evaluate Ginkgo Bioworks' management efficiency
Ginkgo Bioworks Holdings has Return on Asset of (0.1967) % which means that on every $100 spent on assets, it lost $0.1967. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.6034) %, meaning that it generated no profit with money invested by stockholders. Ginkgo Bioworks' management efficiency ratios could be used to measure how well Ginkgo Bioworks manages its routine affairs as well as how well it operates its assets and liabilities. As of May 5, 2025, Return On Tangible Assets is expected to decline to -0.44. In addition to that, Return On Capital Employed is expected to decline to -0.46. At present, Ginkgo Bioworks' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 107.1 M, whereas Net Tangible Assets are forecasted to decline to about 1.1 B.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 13.80 | 13.11 | |
| Tangible Book Value Per Share | 12.40 | 11.78 | |
| Enterprise Value Over EBITDA | (0.86) | (0.90) | |
| Price Book Value Ratio | 0.71 | 0.68 | |
| Enterprise Value Multiple | (0.86) | (0.90) | |
| Price Fair Value | 0.71 | 0.68 | |
| Enterprise Value | 415.8 M | 395 M |
Leadership effectiveness at Ginkgo Bioworks Holdings is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Enterprise Value Revenue 1.3897 | Revenue | Quarterly Revenue Growth 0.262 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ginkgo Bioworks insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ginkgo Bioworks' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ginkgo Bioworks insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ginkgo Bioworks Corporate Filings
| 29th of April 2025 Other Reports | ViewVerify | |
F4 | 23rd of April 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 24th of March 2025 Other Reports | ViewVerify |
Ginkgo Bioworks Earnings per Share Projection vs Actual
Ginkgo Bioworks Corporate Management
| Anna Wagner | Senior Development | Profile | |
| Samantha Sutton | Head People | Profile | |
| Joaquim Marques | Head Chemistry | Profile | |
| Mark Dmytruk | Chief Officer | Profile | |
| Reshma Shetty | President, Founder | Profile | |
| Joshua Dunn | Head Design | Profile | |
| Thomas Knight | Founder | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ginkgo Bioworks Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ginkgo Bioworks. If investors know Ginkgo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ginkgo Bioworks listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (10.54) | Revenue Per Share | Quarterly Revenue Growth 0.262 | Return On Assets | Return On Equity |
The market value of Ginkgo Bioworks Holdings is measured differently than its book value, which is the value of Ginkgo that is recorded on the company's balance sheet. Investors also form their own opinion of Ginkgo Bioworks' value that differs from its market value or its book value, called intrinsic value, which is Ginkgo Bioworks' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ginkgo Bioworks' market value can be influenced by many factors that don't directly affect Ginkgo Bioworks' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ginkgo Bioworks' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ginkgo Bioworks is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ginkgo Bioworks' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.